B-Y. Ryoo
Impact in
- Hepatology top 5%
- Hepatocellular Carcinoma Treatment and Prognosis
- Gastroenterology top 5%
- Gastrointestinal Tumor Research and Treatment
Papers in
- Oncology 22
- Colorectal Cancer Treatments and Studies 9
- Pancreatic and Hepatic Oncology Research 6
- Cancer Treatment and Pharmacology 4
-
- Gastric Cancer Management and Outcomes 8
- Lung Cancer Treatments and Mutations 6
- Co-authors
- Y-K. Kang (4 shared papers)M.-H. Ryu (3 shared papers)Shuai Yang (1 shared paper)Hye Jin Kang (1 shared paper)Jin Ho Baek (1 shared paper)Young Joo Min (1 shared paper)Ann‐Lii Cheng (6 shared papers)Heon‐Jin Lee (2 shared papers)
- Journals
- Annals of Oncology (21 papers)British Journal of Cancer (5 papers)Journal of Clinical Oncology (3 papers)ESMO Open (3 papers)European Journal of Cancer (3 papers)
- Partner nations
- South KoreaUnited StatesGermany
In The Last Decade
B-Y. Ryoo
31 papers receiving 584 citations
B-Y. Ryoo's Hit Papers
Peers
Comparison fields: 5 of 45
- Hepatology 138
- Gastroenterology 74
- Pulmonary and Respiratory Medicine 272
- Oncology 201
- Internal Medicine 14
Countries citing papers authored by B-Y. Ryoo
This map shows the geographic impact of B-Y. Ryoo's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by B-Y. Ryoo with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites B-Y. Ryoo more than expected).
Fields of papers citing papers by B-Y. Ryoo
This network shows the impact of papers produced by B-Y. Ryoo. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by B-Y. Ryoo. The network helps show where B-Y. Ryoo may publish in the future.
Co-authors
The 25 scholars most cited alongside B-Y. Ryoo, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.
All Works
Showing the 20 most-cited of 37 papers — load more, or switch the sort, to bring in the rest.
| # | Work | ||
|---|---|---|---|
| 1 | LBA34 Primary results from the phase III LEAP-002 study: Lenvatinib plus pembrolizumab versus lenvatinib as first-line (1L) therapy for advanced hepatocellular carcinoma (aHCC) Hit paper breakdown → | 2022 | 138 |
| 2 | 2008 | 117 | |
| 3 | 2004 | 74 | |
| 4 | 2012 | 70 | |
| 5 | 2006 | 56 | |
| 6 | 2013 | 49 | |
| 7 | 2016 | 14 | |
| 8 | 2022 | 9 | |
| 9 | 2022 | 8 | |
| 10 | 2023 | 7 | |
| 11 | 2023 | 5 | |
| 12 | 2006 | 5 | |
| 13 | 2015 | 5 | |
| 14 | 2020 | 4 | |
| 15 | 2020 | 4 | |
| 16 | 1999 | 3 | |
| 17 | 2019 | 3 | |
| 18 | 2022 | 3 | |
| 19 | 2023 | 1 | |
| 20 | 2023 | 1 |
About B-Y. Ryoo
B-Y. Ryoo is a scholar working on Oncology, Pulmonary and Respiratory Medicine, Hepatology, Surgery and Cancer Research, having authored 37 papers that have together received 587 indexed citations. Recurring topics across this work include Hepatocellular Carcinoma Treatment and Prognosis (12 papers), Colorectal Cancer Treatments and Studies (9 papers), Gastric Cancer Management and Outcomes (8 papers), Cholangiocarcinoma and Gallbladder Cancer Studies (7 papers), Pancreatic and Hepatic Oncology Research (6 papers), Lung Cancer Treatments and Mutations (6 papers), Cancer Genomics and Diagnostics (5 papers) and Cancer Treatment and Pharmacology (4 papers). The work is most often cited by research in Hepatology (138 citations), Gastroenterology (74 citations), Pulmonary and Respiratory Medicine (272 citations), Oncology (201 citations) and Internal Medicine (14 citations). B-Y. Ryoo has collaborated with scholars based in South Korea, United States and Germany. Frequent co-authors include Y-K. Kang, M.-H. Ryu, Shuai Yang, Hye Jin Kang, Jin Ho Baek, Young Joo Min, Ann‐Lii Cheng, Heon‐Jin Lee, Dae Young Zang and Heung-Moon Chang. Their work appears in journals such as Annals of Oncology, British Journal of Cancer, Journal of Clinical Oncology, ESMO Open and European Journal of Cancer.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.